Celldex Therapeutics CLDX

$31.65 -0.53 (-1.65%)

Valuation

Market cap
2,485,474,000
Revenue TTM
$1,550,000
Net income TTM
$-258,760,000
PE ratio
0.00
Forward PE
—
Profit margin
-16,694.19%
Debt to equity
0.00

Trading

Volume
2,405,700
Avg volume
1,331,072
Day's range
$30.98 – $32.54
Shares out
78,530,000
Stochastic %K
16%
Beta
0.90
Analysts
Strong Sell
Price target
$63.28

Price

Company profile

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159),...

Show more

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.

Industry
Biotechnology
Sector
Healthcare
Phone
908 200 7500
Website
https://www.celldex.com
Address
Perryville III Building, Suite 220 53 Frontage Road, Hampton, United States

Latest news

Stocktwits

Merlintrader Oct 4, 8:27 PM
Celldex ($CLDX) Stock Hub: Can Barzolvolimab Turn Two Phase 3 Wins Into a 2027 BLA? Explore the company, catalysts and risks in our research hub. https://www.merlintrader.com/celldex-therapeutics-cldx-stock-hub/
0 replies
TheSuper Oct 1, 9:37 PM
$CLDX Still!
0 replies
Steve1545 Sep 30, 11:00 PM
$CLDX so
1 replies
lucabrix Sep 30, 7:17 PM
$CLDX Reply!
0 replies
Wolfofwannabe Sep 30, 1:31 PM
$CLDX
0 replies
TheSuper Sep 29, 6:44 PM
$CLDX still
0 replies
ProfitFromProcess Sep 28, 4:39 PM
$CLDX moving!
0 replies
TheSuper Sep 24, 6:16 PM
$CLDX @Timefortendies77
1 replies